Invivyd

IVVD

Market cap $241M

Overview Fund Activity

1.15 USD

-0.11

8.73%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

1.21

+0.06

5.22%

1 day

-8.73%

5 days

-10.85%

1 month

97.9%

3 months

58.23%

6 months

50.48%

Year to date

139.58%

1 year

3.6%

5 years

-94.49%

10 years

-94.49%

About: Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Employees: 100

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

5,500% more call options, than puts

Call options by funds: $112K | Put options by funds: $2K

1% more capital invested

Capital invested by funds: $42.6M [Q1] → $43.2M (+$588K) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

8.32% less ownership

Funds ownership: 58.71% [Q1] → 50.39% (-8.32%) [Q2]

16% less funds holding

Funds holding: 80 [Q1] → 67 (-13) [Q2]

45% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 29

50% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 26

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$1

13% downside

Avg. target

$3.67

219% upside

High target

$5

335% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about IVVD published over the past 30 days

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease.

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the SPEAR Study Group has issued their consensus recommendation for a clinical study design to evaluate the effects of monoclonal antibody (mAb) therapy on Long COVID. The recommendation will be presented for consideration to RECOVER-TLC, an NIH initiative devoted to testing potential treatments for Long COVID.

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Invivyd's monoclonal antibody (mAb) VYD2311 is a prophylactic for COVID has greater efficacy and less side effects than COVID vaccines. The current administration's clear goal of minimizing the prevalence of COVID vaccines should only hasten the realization of VYD2311 as a superior treatment option for those at risk. The FDA recently agreed to a rather favorable regulatory pathway for VYD2311, in start contrast to the punitive regulatory changes it made to COVID vaccine development in May.

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences: Cantor Global Healthcare Conference 2025 Fireside Chat Date: Wednesday, September 3, 2025Fireside Chat Time: 2:10 PM ETLocation: New York, NY H.C.

Invivyd to Participate in Upcoming Investor Conferences

This Fidelity stock rockets over 70% on COVID-19 alternative vaccine; Time to buy?

Invivyd (NASDAQ: IVVD), a biopharmaceutical company focused on developing protection against serious viral infectious diseases, is back in the spotlight with notable share price movement.

This Fidelity stock rockets over 70% on COVID-19 alternative vaccine; Time to buy?

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the closing of its previously announced underwritten public offering of 89,234,480 shares of its common stock, which includes the exercise in full by the underwriter of its option to purchase an additional 14,423,076 shares of common stock, at a public offering price of $0.52 per share and pre-funded warrants to purchase 21,342,442 shares of its common stock at a public offering price of $0.5199 per pre-funded warrant, which represents the per share price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. All of the shares and pre-funded warrants were offered by Invivyd. The gross proceeds from this offering were approximately $57.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Invivyd.

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0.52 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 21,342,442 shares of its common stock at a price of $0.5199 per pre-funded warrant.

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Invivyd. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

WALTHAM, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA® (pemivibart) against the currently dominant and growing XFG variant of SARS-CoV-2. Notably, and consistent with all dominant variants for the past three years, XFG did not generate any meaningful change to the in vitro neutralization activity of pemivibart or VYD2311, the company's next generation COVID-19 monoclonal antibody (mAb) candidate, as the epitopes targeted by pemivibart and VYD2311 remain structurally intact. PEMGARDA (pemivibart) is authorized by the U.S. Food and Drug Administration (FDA) for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients.

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Zacks Investment Research

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.4 per share a year ago.

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™